Zhouling Xie
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present).
Journal: Expert opinion on therapeutic patents
Published: July 27, 2026
Evolving Strategies for Previously Drugged Therapeutic Targets: Medicinal Chemistry Insights from Paradigmatic Cases.
Journal: Journal of medicinal chemistry
Published: June 02, 2026
Discovery of the First Highly Potent, Selective, Irreversible Small-Molecule Factor XIIa Inhibitor for Treating Sepsis.
Journal: Journal of medicinal chemistry
Published: May 14, 2026
Plasma Kallikrein Inhibitors for Multiple Disorders: Current Advances and Perspectives.
Journal: Journal of medicinal chemistry
Published: October 02, 2025
Design, synthesis, and biological evaluation of highly potent and selective hMAO-B inhibitors featuring a tetrahydrobenzo[f][1,4]oxazepine core.
Journal: European journal of medicinal chemistry
Published: June 18, 2025
Structure-Based Discovery of a Highly Selective, Oral Polo-Like Kinase 1 Inhibitor with Potent Antileukemic Activity.
Journal: Journal of medicinal chemistry
Published: February 18, 2025
Drugs targeting peroxisome proliferator-activated receptors.
Journal: Drug discovery today
Published: December 08, 2024
Selective factor XI/XIa inhibitors: a beacon of hope in anticoagulation therapy.
Journal: Future medicinal chemistry
Published: October 07, 2024
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
Journal: Expert opinion on therapeutic patents
Published: July 12, 2024
Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation.
Journal: Journal of medicinal chemistry
Published: June 24, 2024
Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.
Journal: Journal of medicinal chemistry
Published: April 10, 2023
Last Updated: 09/26/2026